CITIUS PHARMACEUTICALS INC (CTXR) Stock Price, Forecast & Analysis
USA - NASDAQ:CTXR - US17322U3068 - Common Stock
CTXR Key Statistics, Chart & Performance
The current stock price of CTXR is 1.01 USD. In the past month the price decreased by -31.76%. In the past year, price decreased by -79.8%.
CTXR Latest News, Press Relases and Analysis
CTXR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.52 | 968.11B | ||
| JNJ | JOHNSON & JOHNSON | 18.81 | 470.23B | ||
| MRK | MERCK & CO. INC. | 10.55 | 232.12B | ||
| PFE | PFIZER INC | 8.06 | 146.63B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.41 | 98.98B | ||
| ZTS | ZOETIS INC | 19.11 | 53.70B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.67 | 23.17B | ||
| VTRS | VIATRIS INC | 4.68 | 12.72B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.91 | 10.92B | ||
| CORT | CORCEPT THERAPEUTICS INC | 86.08 | 7.98B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.86B | ||
| LGND | LIGAND PHARMACEUTICALS | 27.61 | 3.94B |
Related stock screener links
About CTXR
Company Profile
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 23 full-time employees. The company went IPO on 2017-08-03. The firm's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The firm is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
Company Info
CITIUS PHARMACEUTICALS INC
11 Commerce Dr Fl 1
Cranford NEW JERSEY 07016 US
CEO: Myron Holubiak
Employees: 23
Phone: 19089676677
CITIUS PHARMACEUTICALS INC / CTXR FAQ
What does CTXR do?
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 23 full-time employees. The company went IPO on 2017-08-03. The firm's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The firm is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
What is the current price of CTXR stock?
The current stock price of CTXR is 1.01 USD. The price decreased by -8.6% in the last trading session.
What is the dividend status of CITIUS PHARMACEUTICALS INC?
CTXR does not pay a dividend.
What is the ChartMill rating of CITIUS PHARMACEUTICALS INC stock?
CTXR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of CTXR stock?
CITIUS PHARMACEUTICALS INC (CTXR) operates in the Health Care sector and the Pharmaceuticals industry.
How is the valuation of CITIUS PHARMACEUTICALS INC (CTXR) based on its PE ratio?
CITIUS PHARMACEUTICALS INC (CTXR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.96).
How many employees does CITIUS PHARMACEUTICALS INC have?
CITIUS PHARMACEUTICALS INC (CTXR) currently has 23 employees.
CTXR Technical Analysis
CTXR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CTXR. CTXR has a bad profitability rating. Also its financial health evaluation is rather negative.
CTXR Financial Highlights
Over the last trailing twelve months CTXR reported a non-GAAP Earnings per Share(EPS) of -4.96. The EPS decreased by -71.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.1% | ||
| ROE | -63.01% | ||
| Debt/Equity | 0.02 |
CTXR Forecast & Estimates
9 analysts have analysed CTXR and the average price target is 5.1 USD. This implies a price increase of 404.95% is expected in the next year compared to the current price of 1.01.